OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Power of Plasticity—Metabolic Regulation of Hepatic Stellate Cells
Parth Trivedi, Shuang Wang, Scott L. Friedman
Cell Metabolism (2020) Vol. 33, Iss. 2, pp. 242-257
Open Access | Times Cited: 262

Showing 1-25 of 262 citing articles:

Hepatic inflammatory responses in liver fibrosis
Linda Hammerich, Frank Tacke
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 10, pp. 633-646
Closed Access | Times Cited: 322

Liver macrophages in health and disease
Martin Guilliams, Charlotte L. Scott
Immunity (2022) Vol. 55, Iss. 9, pp. 1515-1529
Open Access | Times Cited: 226

Celastrol induces ferroptosis in activated HSCs to ameliorate hepatic fibrosis via targeting peroxiredoxins and HO-1
Piao Luo, Dandan Liu, Qian Zhang, et al.
Acta Pharmaceutica Sinica B (2021) Vol. 12, Iss. 5, pp. 2300-2314
Open Access | Times Cited: 203

Hepatic stellate cells in physiology and pathology
Dakota R. Kamm, Kyle S. McCommis
The Journal of Physiology (2022) Vol. 600, Iss. 8, pp. 1825-1837
Open Access | Times Cited: 155

Oxidative Stress in Liver Pathophysiology and Disease
Abdolamir Allameh, Reyhaneh Niayesh‐Mehr, Azadeh Aliarab, et al.
Antioxidants (2023) Vol. 12, Iss. 9, pp. 1653-1653
Open Access | Times Cited: 150

Hexokinase 2-mediated gene expression via histone lactylation is required for hepatic stellate cell activation and liver fibrosis
Hyunsoo Rho, Alexander R. Terry, Constantinos Chronis, et al.
Cell Metabolism (2023) Vol. 35, Iss. 8, pp. 1406-1423.e8
Open Access | Times Cited: 126

Pericytes in the tumor microenvironment
Zhongyi Jiang, Jing Zhou, Luohong Li, et al.
Cancer Letters (2023) Vol. 556, pp. 216074-216074
Open Access | Times Cited: 74

Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Maurizio Parola, Massimo Pinzani
Molecular Aspects of Medicine (2023) Vol. 95, pp. 101231-101231
Open Access | Times Cited: 70

Metabolic reprogramming in liver fibrosis
Paul Horn, Frank Tacke
Cell Metabolism (2024) Vol. 36, Iss. 7, pp. 1439-1455
Open Access | Times Cited: 67

Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)
Shuang Wang, Scott L. Friedman
Science Translational Medicine (2023) Vol. 15, Iss. 716
Open Access | Times Cited: 56

Treating NASH by targeting peroxisome proliferator-activated receptors
Bart Staels, Laura Butruille, Sven Francque
Journal of Hepatology (2023) Vol. 79, Iss. 5, pp. 1302-1316
Open Access | Times Cited: 45

Liver Fibrosis: From Basic Science towards Clinical Progress, Focusing on the Central Role of Hepatic Stellate Cells
Hikmet Akkız, Robert K. Gieseler, Ali Canbay
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 14, pp. 7873-7873
Open Access | Times Cited: 17

Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits
Joyce Yip, Grace Shu Hui Chiang, I Lee, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 1, pp. 364-364
Open Access | Times Cited: 2

Peroxisome proliferator–activated receptor delta and liver diseases
Tomoo Yamazaki, Edward E. Cable, Bernd Schnabl
Hepatology Communications (2025) Vol. 9, Iss. 2
Open Access | Times Cited: 2

Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics
Xiao Ma, Tengda Huang, Xi Chen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 2

Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosis
Raquel A. Martinez García de la Torre, Júlia Vallverdú, Zhixin Xu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 2

Integrative Metabolism in MASLD and MASH: Pathophysiology and Emerging Mechanisms
Gregory R. Steinberg, Celina M Valvano, William De Nardo, et al.
Journal of Hepatology (2025)
Open Access | Times Cited: 2

SREBP-1c and lipogenesis in the liver: an update
Pascal Ferré, Franck Phan, Fabienne Foufelle
Biochemical Journal (2021) Vol. 478, Iss. 20, pp. 3723-3739
Closed Access | Times Cited: 93

Fibroblasts as confederates of the immune system
Donovan Correa‐Gallegos, Dongsheng Jiang, Yuval Rinkevich
Immunological Reviews (2021) Vol. 302, Iss. 1, pp. 147-162
Open Access | Times Cited: 82

Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies
Youngmin A. Lee, Scott L. Friedman
Journal of Internal Medicine (2021) Vol. 291, Iss. 1, pp. 11-31
Open Access | Times Cited: 73

Roles of Ceramides in Non-Alcoholic Fatty Liver Disease
Éric Hajduch, Floriane Lachkar, Pascal Ferré, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 4, pp. 792-792
Open Access | Times Cited: 72

Metabolic Changes of Hepatocytes in NAFLD
Qianrang Lu, Xinyao Tian, Hao Wu, et al.
Frontiers in Physiology (2021) Vol. 12
Open Access | Times Cited: 71

Hypoxia, Hypoxia-Inducible Factors and Liver Fibrosis
Beatrice Foglia, Erica Novo, Francesca Protopapa, et al.
Cells (2021) Vol. 10, Iss. 7, pp. 1764-1764
Open Access | Times Cited: 68

Developing tissue engineering strategies for liver regeneration
Jinglin Wang, Danqing Huang, Hang Yu, et al.
Engineered Regeneration (2022) Vol. 3, Iss. 1, pp. 80-91
Open Access | Times Cited: 63

Page 1 - Next Page

Scroll to top